

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty 0 1579-0869
Dkt.

C# M#

SCHWINN, Debra A.

TC/A.U. 1634

Serial No. 10/715,844

Examiner: Goldberg, J.A.

Filed: November 19, 2003

Date: October 3, 2006

Title: ADRENERGIC RECEPTORS



IFW
\$

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.**

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$200.00 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add
\$360.00 (1203)/\$180.00 (2203) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s)
One Month Extension \$120.00 (1251)/\$60.00 (2251)
Two Month Extensions \$450.00 (1252)/\$225.00 (2252)
Three Month Extensions \$1020.00 (1253)/\$510.00 (2253)
Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)
Five Month Extensions \$2160.00 (1255)/\$1080.00 (2255) \$
Terminal disclaimer enclosed, add \$130.00 (1814)/ \$65.00 (2814) \$

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$ 180.00

Assignment Recording Fee \$40.00 (8021) \$ 0.00

Other: \$ 0.00

TOTAL FEE (CREDIT CARD PAYMENT FORM ATTACHED) \$ 180.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor
Arlington, Virginia 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHWINN, Debra A.

Serial No. 10/715,844

Filed: November 19, 2003

For: ADRENERGIC RECEPTORS



Confirmation No. 3968

Atty. Ref.: 01579-0869

Group: 1634

Examiner: Goldberg, J.A.

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 3, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO/SB/08a Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO/SB/08a together with copies (as
may be required) of each identified document and a translation or a
concise explanation of each non-English language document (such
as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];
and
 - ☐ a) The required Statement made in item 8 below; or
 - ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith;
and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

SCHWINN, Debra A.
Serial No. 10/715,844
October 3, 2006

- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.


Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION TYPE

(Use several sheets if necessary)



Atty. Docket No.

1579-869

Serial No.

10/715,844

Applicant

SCHWINN, Debra A.

Filing Date

November 19, 2003

TC/A.U.

1634

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Xie et al, "α1A-Adrenergic receptor polymorphism: association with ethnicity but not essential hypertension", Pharmacogenetics 9:651-656 (1999)
	Shibata et al, α1A-Adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy", Br. J. Pharmacology 118:1403-1408 (1996) – Abstract
	Schwinn et al, "Novel alpha1A-Adrenergic receptor SNPs and Human hypertension", Human Mutation 17(4):341 (2000) – Abstract No. 94
	Clark et al, "ADRA1A Promoter Polymorphisms Associated With Schizophrenia In Spanish Isolate", Am. J. of Med. 130B(1) (2004) - Abstract No. P7.24
	Tamm et al, "Antisense therapy in oncology: new hope for an old idea?", The Lancet 358:489-497 (2001)
	Lei et al, "Novel human α _{1a} -adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function", Naunyn-Schmiedeberg's Arch. Pharmacol. 371:229-239 (2005)
	Price et al, "Acute Agonist-mediated Desensitization of the Human α _{1a} -Adrenergic Receptor Is Primarily Independent of Carboxyl Terminus Regulation", The Journal of Biological Chemistry 277(11):9570-9579 (2002)
	Podgoreanu and Schwinn, "New Paradigms in Cardiovascular Medicine, Emerging Technologies and Practices: Perioperative Genomics", J. Am. Coll. Cardiol. 46(11):1965-1977 (2005)
	Hawrylyshyn et al, "Update on human α ₁ -adrenoceptor subtype signaling and genomic organization", TRENDS in Pharmacological Sciences 25(9):449-445 (2004)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.